Alfonso Duenas Gonzalez, Medical Oncologist and Senior Researcher at National Cancer Institute of Mexico, shared a post on X:
“The PROT-BM trial supports the use of prophylactic cranial irradiation (PCI) to reduce brain metastases and improve survival in high-risk NSCLC, particularly in low- and middle-income countries without access to third-generation TKIs.
- The study is fundamentally flawed. Critical Issues: Protocol violations: 17-21 patients included who did not meet the study’s own high-risk definition.
- Unacknowledged imbalance: Significantly more EGFR/ALK mutations in PCI arm (p=0.029); paper falsely claims “balanced baseline characteristics.” Inconsistent data.
- Death counts vary across the 3 papers (44 vs 64 vs 58).
- Misleading conclusions: EGFR/ALK status was the stronger OS predictor.”
Other articles about NSCLC on OncoDaily.